Theranexus S.A. (3VG)
XMUN 
Summary
3VG Chart
Theranexus S.A. (3VG) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Theranexus S.A. ever had a stock split?
Theranexus S.A. Profile
| Biotechnology Industry | Healthcare Sector | Mr. Mathieu Charvériat CEO | XMUN Exchange | FR0013286259 ISIN |
| France Country | 10 Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
Theranexus Société Anonyme is a forward-thinking biopharmaceutical company with a focus on developing innovative drug candidates specifically designed to treat central nervous system (CNS) disorders. Established in the year 2013 and having its headquarters in the vibrant city of Lyon, France, Theranexus is at the forefront of addressing the complex challenges associated with CNS disorders. The company's dedication to scientific excellence and innovation is evident in its commitment to advancing its research programs and clinical studies.
Products and Services
-
Batten-1 (Drug Candidate)
As Theranexus' pioneering drug candidate, Batten-1 represents a significant advancement in the treatment of Batten disease, a rare, fatal, autosomal recessive neurodegenerative disorder. This condition primarily affects children, leading to symptoms such as seizures, visual impairment, and cognitive decline. Currently under Phase ½ clinical study, Batten-1 embodies Theranexus' commitment to addressing unmet medical needs within the realm of CNS disorders. The development of Batten-1 underscores the company's dedication to leveraging scientific research for the creation of therapeutic solutions that have the potential to drastically improve patient outcomes.
